Patient baseline demographic characteristics and history of PsA drug therapy of all patients with PsA at time of enrolment
| All patients n=1542 | Patients with PsA categorised by skin and joint disease activity | |||||||
| 0% | >0% to 3% | >3% | ||||||
| Low n=258 (16.7) | M/H 109 (7.1) | Low 447 (29.0) | M/H 227 (14.7) | Low 256 (16.6) | M/H 245 (15.9) | P value | ||
| Age (years), n | 1522 | 257 | 109 | 442 | 220 | 253 | 241 | <0.001 |
| Mean (SD) | 53.7±13.2 | 54.5±12.6 | 57.9±10.8 | 53.5±13.5 | 55.3±13.2 | 52.1±13.7 | 51.8±13.4 | |
| Gender, n | 1531 | 256 | 109 | 445 | 225 | 252 | 244 | <0.001 |
| n (%) Female | 810 (52.9) | 129 (50.4) | 74 (67.9) | 227 (51.0) | 125 (55.6) | 112 (44.4) | 143 (58.6) | |
| Race, n | 1491 | 252 | 105 | 430 | 217 | 249 | 238 | 0.021 |
| White, n (%) | 1408 (94.4) | 240 (95.2) | 99 (94.3) | 415 (96.5) | 206 (94.9) | 234 (94.0) | 214 (89.9) | |
| Insurance type, n Private only Other+private Other None | 1514 1118 (73.8) 113 (7.5) 255 (16.8) 28 (1.9) | 255 194 (76.1) 17 (6.7) 39 (15.3) 5 (2.0) | 107 69 (64.5) 12 (11.2) 22 (20.6) 4 (3.7) | 435 344 (79.1) 26 (6.0) 59 (13.6) 6 (1.4) | 223 143 (64.1) 27 (12.1) 49 (22.0) 4 (1.8) | 252 200 (79.4) 15 (6.0) 31 (12.3) 6 (2.4) | 242 168 (69.4) 16 (6.6) 55 (22.7) 3 (1.2) | <0.001 0.037 0.002 0.617 |
| Smoking status, n | 1508 | 253 | 109 | 435 | 218 | 251 | 242 | |
| Never, n (% of N) | 796 (52.8) | 143 (56.5) | 67 (61.5) | 232 (53.3) | 119 (54.6) | 123 (49.0) | 112 (46.3) | 0.060 |
| Former, n (% of N) Current, n (% of N) | 544 (36.1) 168 (11.1) | 95 (37.6) 15 (5.9) | 29 (26.6) 13 (11.9) | 161 (37.0) 42 (9.7) | 76 (34.9) 23 (10.6) | 95 (37.9) 33 (13.2) | 88 (36.4) 42 (17.4) | 0.400 0.002 |
| BMI, n | 1472 | 251 | 104 | 415 | 215 | 250 | 237 | 0.0001 |
| Mean (SD) | 31.5±7.2 | 30.4±6.2 | 32.2±8.3 | 30.7±6.7 | 31.6±7.2 | 31.7±7.4 | 33.1±7.7 | |
| BMI categories Normal (BMI <25) Overweight (25≤BMI<30) Obese (BMI ≥30) | 248 (16.9) 445 (30.2) 779 (52.9) | 46 (18.3) 88 (35.1) 117 (46.6) | 22 (21.1) 26 (25.0) 56 (53.9) | 83 (20.0) 126 (30.4) 206 (49.6) | 38 (17.7) 56 (26.1) 121 (56.3) | 35 (14.0) 84 (33.6) 131 (52.4) | 24 (10.1) 65 (27.4) 148 (62.5) | 0.016 0.149 0.009 |
| PsA disease duration (years) | ||||||||
| From diagnosis date, n | 1485 | 223 | 130 | 369 | 284 | 217 | 262 | 0.0827 |
| Median (IQR) | 9.0 (4.0, 16.0) | 10.0 (4.0, 18.0) | 8.5 (4.0, 19.0) | 8.0 (4.0, 15.0) | 8.0 (4.0, 15.0) | 10.0 (5.0, 18.0) | 9.0 (4.0, 16.0) | |
| PsO disease duration (years) | ||||||||
| From diagnosis date, n | 923 | 126 | 43 | 291 | 125 | 184 | 154 | 0.9570 |
| Median (IQR) | 18.0 (9.0, 28.0) | 18.0 (10.0, 28.0) | 16.0 (7.0, 31.0) | 17.0 (9.0, 26.0) | 16.0 (7.0, 32.0) | 19.0 (11.0, 28.0) | 17.0 (10.0, 29.0) | |
| Work status, n | 1524 | 257 | 108 | 444 | 222 | 252 | 241 | |
| Full/part-time, n (% of N) Student/WFH, n (% of N) Retired, n (% of N) Disabled, n (% of N) | 959 (62.9) 103 (6.8) 326 (21.4) 136 (8.9) | 169 (65.8) 19 (7.4) 60 (23.4) 9 (3.5) | 51 (47.2) 3 (2.8) 36 (33.3) 18 (16.7) | 307 (69.1) 29 (6.5) 89 (20.1) 19 (4.3) | 117 (52.7) 15 (6.8) 55 (24.8) 35 (15.8) | 177 (70.2) 17 (6.8) 44 (17.5) 14 (5.6) | 138 (57.3) 20 (8.3) 42 (17.4) 41 (17.0) | <0.001 0.575 0.006 <0.001 |
| Prior therapy | ||||||||
| Hx of prior biologic use | ||||||||
| Any biologic, n (%) | 966 (62.7) | 177 (68.9) | 70 (64.2) | 286 (64.0) | 132 (58.2) | 161 (62.9) | 140 (57.4) | 0.088 |
| Current therapy | ||||||||
| Current DMARD therapy | 1484 | 245 | 103 | 428 | 221 | 252 | 235 | |
| Not on DMARD therapy | 266 (17.9) | 29 (11.8) | 13 (12.6) | 54 (12.6) | 61 (27.6) | 36 (14.3) | 73 (31.1) | <0.001 |
| MTX or other csDMARDs (no biologics) only | 430 (29.0) | 60 (24.5) | 30 (29.1) | 134 (31.3) | 68 (30.8) | 71 (28.2) | 67 (28.5) | 0.553 |
| Biologics/tsDMARDs | 788 (53.1) | 156 (63.7) | 60 (58.3) | 240 (56.1) | 92 (41.6) | 145 (57.5) | 95 (40.4) | <0.001 |
P value represents comparisons between CDAI/BSA subgroups and were analysed using χ2 tests, Fisher’s exact tests, t-tests or Wilcoxon-Mann-Whitney tests, as appropriate. Skin severity by levels of BSA: 0%, >0% to 3% and >3%; joint activity by levels of CDAI: low and M/H=moderate/high; BMI: based on the CDC cut-offs for normal/underweight (under 25); overweight (25.0–29.9); and obese (30.0 and above). For insurance, Other includes Medicare and Medicaid.
BMI, body mass index; BSA, body surface area; CDAI, Clinical Disease Activity Index; CDC, Centers for Disease Control and Prevention; DMARD, disease-modifying antirheumatic drug; Hx, history; MTX, methotrexate; PsA, psoriatic arthritis; WFH, work from home; csDMARD, conventional synthetic DMARD; tsDMARD, targeted synthetic DMARD.